Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Worldwide Breast Cancer Monoclonal Antibodies Market To Post A Revenue Of 13.7 Billion By 2020

Wednesday, September 21, 2016 1:54
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell.

Publisher’s analysts forecast the global breast cancer monoclonal antibodies (mAbs) market to post a revenue of 13.7 billion by 2020.

For more information about this report:               

Covered in this report 
The report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer.

The market is divided into the following segments based on geography: 
- Americas

Publisher’s report, Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
- Amgen 
- Roche 
- Mylan


Request Sample Copy at                      


Other prominent vendors 
- Array BioPharma
- AstraZeneca
- Biocad
- Boehringer Ingelheim
- Bristol-Myers Squibb 
- Celldex Therapeutics
- Celltrion
- Chugai Pharmaceutical
- Daiichi Sankyo 
- DARA Biosciences
- Eddingpharm 
- Eisai 
- Galena Biopharma
- GlaxoSmithKline
- Halozyme Therapeutics
- Hospira 
- ImmunoGen
- Immunomedics
- MacroGenics
- Merck
- Novartis
- Oncothyreon
- Pfizer 
- ProStrakan
- Puma Biotechnology
- Seattle Genetics
- Sun Pharmaceutical Industries 
- Synta Pharmaceuticals
- Teva Pharmaceuticals

Market driver 
- Reimbursement benefits for breast cancer mAbs
- For a full, detailed list, view our report 

Market challenge 
- Absence of adequate diagnosis and screening procedures for early detection
- For a full, detailed list, view our report 

Market trend 
- Emergence of targeted and combination therapies for breast cancer
- For a full, detailed list, view our report 


Inquire for Report at                      


Contact Us:

Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.